Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line

Frontiers in Cell and Developmental Biology

Volumn 3, Issue MAR, 2015, Pages

  Moore, Joseph B ^a,b   Loeb, David M ^a   Hong, Kyung U ^b   Sorensen, Poul H ^c   Triche, Timothy J ^d   Lee, David W ^e   Barbato, Michael I ^a,f   Arceci, Robert J ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug resistance; Epigenetics; Ewing sarcoma; Induced pluripotent stem cells; Reprogramming

Indexed keywords

EID: 84938934272     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2015.00015     Document Type: Article

References (49)

1. Arvand, A., and Denny, C. T. (2001). Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20, 5747-5754. doi: 10.1038/sj.onc.1204598
2. Awad, O., Yustein, J. T., Shah, P., Gul, N., Katuri, V., O'Neill, A., et al. (2010). High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS ONE. 5:e13943. doi: 10.1371/journal.pone.0013943
3. Barber-Rotenberg, J. S., Selvanathan, S. P., Kong, Y., Erkizan, H. V., Snyder, T. M., Hong, S. P., et al. (2012). Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 3, 172-182
4. Braunreiter, C. L., Hancock, J. D., Coffin, C. M., Boucher, K. M., and Lessnick, S. L. (2006). Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle 5, 2753-2759. doi: 10.4161/cc.5.23.3505
5. Brill, L. M., Xiong, W., Lee, K. B., Ficarro, S. B., Crain, A., Xu, Y., et al. (2009). Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-213. doi: 10.1016/j.stem.2009.06.002
6. Brown, H. F., Unger, C., and Whitehouse, A. (2013). Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line. J. Virol. 87, 7127-7139. doi: 10.1128/JVI.03147-12
7. Burchill, S. A. (2003). Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J. Clin. Pathol. 56, 96-102. doi: 10.1136/jcp.56.2.96
8. Carette, J. E., Pruszak, J., Varadarajan, M., Blomen, V. A., Gokhale, S., Camargo, F. D., et al. (2010). Generation of iPSCs from cultured human malignant cells. Blood 115, 4039-4042. doi: 10.1182/blood-2009-07-231845
9. Chou, B. K., Mali, P., Huang, X., Ye, Z., Dowey, S. N., Resar, L. M., et al. (2011). Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 21, 518-529. doi: 10.1038/cr.2011.12
10. Dini, G., Funghini, S., Witort, E., Magnelli, L., Fanti, E., Rifkin, D. B., et al. (2002). Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential. J. Cell. Physiol. 193, 64-72. doi: 10.1002/jcp.10152
11. Erkizan, H. V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J. S., Yuan, L., et al. (2009). A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat. Med. 15, 750-756. doi: 10.1038/nm.1983
12. Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J., Pritchard, D. J., et al. (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694-701. doi: 10.1056/NEJMoa020890
13. Grohar, P. J., Woldemichael, G. M., Griffin, L. B., Mendoza, A., Chen, Q. R., Yeung, C., et al. (2011). Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J. Natl. Cancer Inst. 103, 962-978. doi: 10.1093/jnci/djr156
14. Hancock, J. D., and Lessnick, S. L. (2008). A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7, 250-256. doi: 10.4161/cc.7.2.5229
15. Hochedlinger, K., Blelloch, R., Brennan, C., Yamada, Y., Kim, M., Chin, L., et al. (2004). Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875-1885. doi: 10.1101/gad.1213504
16. Hotta, A., Cheung, A. Y., Farra, N., Garcha, K., Chang, W. Y., Pasceri, P., et al. (2009). EOS lentiviral vector selection system for human induced pluripotent stem cells. Nat. Protoc. 4, 1828-1844. doi: 10.1038/nprot.2009.201
17. Hu-Lieskovan, S., Zhang, J., Wu, L., Shimada, H., Schofield, D. E., and Triche, T. J. (2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 65, 4633-4644. doi: 10.1158/0008-5472.CAN-04-2857
18. Juergens, H., Daw, N. C., Geoerger, B., Ferrari, S., Villarroel, M., Aerts, I., et al. (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534-4540. doi: 10.1200/JCO.2010.33.0670
19. Kumano, K., Arai, S., Hosoi, M., Taoka, K., Takayama, N., Otsu, M., et al. (2012). Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119, 6234-6242. doi: 10.1182/blood-2011-07-367441
20. Lessnick, S. L., Dacwag, C. S., and Golub, T. R. (2002). The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1, 393-401. doi: 10.1016/S1535-6108(02)00056-9
21. Lessnick, S. L., and Ladanyi, M. (2012). Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu. Rev. Pathol. 7, 145-159. doi: 10.1146/annurev-pathol-011110-130237
22. Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., et al. (2012). Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 256-262. doi: 10.1200/JCO.2011.37.4355
23. May, W. A., Arvand, A., Thompson, A. D., Braun, B. S., Wright, M., and Denny, C. T. (1997). EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat. Genet. 17, 495-497. doi: 10.1038/ng1297-495
24. May, W. A., Gishizky, M. L., Lessnick, S. L., Lunsford, L. B., Lewis, B. C., Delattre, O., et al. (1993a). Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. U.S.A. 90, 5752-5756. doi: 10.1073/pnas.90.12.5752
25. May, W. A., Grigoryan, R. S., Keshelava, N., Cabral, D. J., Christensen, L. L., Jenabi, J., et al. (2013). Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS ONE 8:e80060. doi: 10.1371/journal.pone.0080060
26. May, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., et al. (1993b). The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell Biol. 13, 7393-7398
27. McKinsey, E. L., Parrish, J. K., Irwin, A. E., Niemeyer, B. F., Kern, H. B., Birks, D. K., et al. (2011). A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30, 4910-4920. doi: 10.1038/onc.2011.197
28. Mills, J., Matos, T., Charytonowicz, E., Hricik, T., Castillo-Martin, M., Remotti, F., et al. (2009). Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo. Hum. Cell 22, 85-93. doi: 10.1111/j.1749-0774.2009.00073.x
29. Miser, J. S., Goldsby, R. E., Chen, Z., Krailo, M. D., Tarbell, N. J., Link, M. P., et al. (2007). Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr. Blood Cancer 49, 894-900. doi: 10.1002/pbc.21233
30. Miyoshi, N., Ishii, H., Nagai, K., Hoshino, H., Mimori, K., Tanaka, F., et al. (2010). Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl. Acad. Sci. U.S.A. 107, 40-45. doi: 10.1073/pnas.0912407107
31. Nishino, K., Toyoda, M., Yamazaki-Inoue, M., Fukawatase, Y., Chikazawa, E., Sakaguchi, H., et al. (2011). DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet. 7:e1002085. doi: 10.1371/journal.pgen.1002085
32. Okada, M., and Yoneda, Y. (2011). The timing of retroviral silencing correlates with the quality of induced pluripotent stem cell lines. Biochim. Biophys. Acta 1810, 226-235. doi: 10.1016/j.bbagen.2010.10.004
33. Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C., Chugh, R., et al. (2014). A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a sarcoma alliance for research through collaboration study. Cancer 120, 2448-2456. doi: 10.1002/cncr.28728
34. Park, I. H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., et al. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141-146. doi: 10.1038/nature06534
35. Pelleitier, M., and Montplaisir, S. (1975). The nude mouse: a model of deficient T-cell function. Methods Achiev. Exp. Pathol. 7, 149-166
36. Prieur, A., Tirode, F., Cohen, P., and Delattre, O. (2004). EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24, 7275-7283. doi: 10.1128/MCB.24.16.7275-7283.2004
37. Ries, L. A. G., and SEER Program (National Cancer Institute (US)). (1999). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program, 1-182
38. Riggi, N., Suva, M. L., Suva, D., Cironi, L., Provero, P., Tercier, S., et al. (2008). EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 68, 2176-2185. doi: 10.1158/0008-5472.CAN-07-1761
39. Rorie, C. J., Thomas, V. D., Chen, P., Pierce, H. H., O'Bryan, J. P., and Weissman, B. E. (2004). The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 64, 1266-1277. doi: 10.1158/0008-5472.CAN-03-3274
40. Scotlandi, K., Benini, S., Nanni, P., Lollini, P. L., Nicoletti, G., Landuzzi, L., et al. (1998). Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58, 4127-4131
41. Sherr, C. J., and DePinho, R. A. (2000). Cellular senescence: mitotic clock or culture shock? Cell 102, 407-410. doi: 10.1016/S0092-8674(00)00046-5
42. Silvany, R. E., Eliazer, S., Wolff, N. C., and Ilaria, R. L. Jr. (2000). Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 19, 4523-4530. doi: 10.1038/sj.onc.1203811
43. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872. doi: 10.1016/j.cell.2007.11.019
44. Utikal, J., Maherali, N., Kulalert, W., and Hochedlinger, K. (2009). Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J. Cell Sci. 122, 3502-3510. doi: 10.1242/jcs.054783
45. Vormoor, J., Baersch, G., Decker, S., Hotfilder, M., Schafer, K. L., Pelken, L., et al. (2001). Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. Pediatr. Res. 49, 332-341. doi: 10.1203/00006450-200103000-00006
46. Wang, X., Lin, G., Martins-Taylor, K., Zeng, H., and Xu, R. H. (2009). Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells. J. Biol. Chem. 284, 34054-34064. doi: 10.1074/jbc.M109.052290
47. Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801. doi: 10.1126/science.1172482
48. Zenali, M. J., Zhang, P. L., Bendel, A. E., and Brown, R. E. (2009). Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. Ann. Clin. Lab. Sci. 39, 160-166
49. Ziegler, K., Bui, T., Frisque, R. J., Grandinetti, A., and Nerurkar, V. R. (2004). A rapid in vitro polyomavirus DNA replication assay. J. Virol. Methods 122, 123-127. doi: 10.1016/j.jviromet.2004.08.012